Safety and Efficacy of Seroquel in First Episode Schizophrenia
Study identifier:BU-5077-0011
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Study Complete
Official Title
Safety and efficacy of Seroquel in first episode schizophrenia
Medical condition
schizophrenia
Phase
Phase 4
Healthy volunteers
No
Study drug
Seroquel and Risperidone
Sex
All
Actual Enrollment
80
Study type
Interventional
Age
18 Years - 35 Years
Date
Study Start Date: 01 May 2002
Primary Completion Date: -
Study Completion Date: 01 Jun 2006
Study design
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Single Blind
Primary Purpose: Treatment
Verification:
Verified 01 Nov 2013 by AstraZeneca Pharmaceuticals
Sponsors
AstraZeneca Pharmaceuticals
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|
Contacts
Investigators
Principal Investigator
AstraZeneca Seroquel Medical Science Director
AstraZenenca
